The results from the analysis of serum and tissues encouraged us to further analyze the histological distributions of FGF19 and its receptor FGFR4 as well as EpCAM, a potential cancer stem cell marker, corresponding to the clinical histological stages, including ST, NASH, CR and HCC. The gene discussed is FGFR4; the disease is metabolic dysfunction-associated steatohepatitis.